Viveve Medical Inc (NASDAQ:VIVE) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 789,170 shares, an increase of 44.2% from the February 28th total of 547,377 shares. Based on an average daily volume of 34,471 shares, the days-to-cover ratio is presently 22.9 days. Approximately 12.6% of the shares of the company are sold short.
Separately, B. Riley reissued a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research report on Wednesday, February 22nd.
Viveve Medical (NASDAQ:VIVE) opened at 6.33 on Friday. The stock has a 50 day moving average of $4.76 and a 200-day moving average of $5.58. Viveve Medical has a 52-week low of $3.75 and a 52-week high of $10.50.
In other news, Director James G. Atkinson purchased 375,000 shares of the company’s stock in a transaction dated Friday, March 17th. The shares were bought at an average price of $4.00 per share, with a total value of $1,500,000.00. Following the completion of the transaction, the director now directly owns 11,525 shares in the company, valued at approximately $46,100. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Patricia Scheller purchased 12,500 shares of the company’s stock in a transaction dated Friday, March 17th. The stock was purchased at an average cost of $4.00 per share, for a total transaction of $50,000.00. Following the transaction, the chief executive officer now owns 45,164 shares of the company’s stock, valued at $180,656. The disclosure for this purchase can be found here. Company insiders own 44.37% of the company’s stock.
A hedge fund recently raised its stake in Viveve Medical stock. HighTower Advisors LLC raised its position in Viveve Medical Inc (NASDAQ:VIVE) by 39.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 910,632 shares of the company’s stock after buying an additional 259,861 shares during the period. HighTower Advisors LLC’s holdings in Viveve Medical were worth $6,574,000 at the end of the most recent quarter. 54.43% of the stock is owned by institutional investors.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.